Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809708 | 0.70 | KDR (0.53) | — | |
| SCHEMBL708243 | 0.62 | KDM4E (0.51) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL5905876 | 0.58 | MEN1 (0.52) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL23913862 | 0.57 | MAPK1 (0.53) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL10066409 | 0.57 | MEN1 (0.54) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL10289108 | 0.57 | HSP90AB1 (0.49) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL10053477 | 0.56 | MEN1 (0.53) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL29788840 | 0.56 | ALDH1A1 (0.65) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL4833617 | 0.56 | MEN1 (0.53) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 | |
| SCHEMBL187941 | 0.56 | KMT2A (0.76) | KDM4EMAPK1L3MBTL1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDM4E 1449/4885MAPK1 443/4885L3MBTL1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.